The UK launch is being initiated by the company's UK partner, Takeda Pharmaceuticals International GmbH.
According to IMS Health, the erectile dysfunction market in the UK was worth approximately USD225m in 2013, the largest ED market in Europe. The product received regulatory approval in Europe in June of 2013 and in August of 2013, Apricus received the national phase approval to have the product marketed in the UK.
In conjunction with manufacturing commercial products, Apricus will provide clinical support for its partners' pre-commercialisation activities in an effort to facilitate a consistent launch of Vitaros throughout 2014.
Perrigo to acquire United States rights for Entocort from AstraZeneca
US FDA approves Boehringer Ingelheim's Pradaxa
Phase II clinical trial for potential treatment of androgenetic alopecia completed by Samumed
Life Sciences Partners collaborates on immuno-oncology with Bristol-Myers Squibb
Arsanis initiates first cohort in Phase one clinical trial of ASN100
Impax introduces generic Avodart (Dutasteride) Capsules, 0.5 mg
Mylan unveils generic FazaClo orally disintegrating tablets for treating schizophrenia